KING OF PRUSSIA, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) ("Vertex” or the "Company”), a global provider of tax technology solutions, today announced that it has been recognized ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

KING OF PRUSSIA, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced that it has ...

Vertex’s research guru has warned that it could take another 15 years to produce a suite of medicines that treat all strains of the disease, saying that a deal with the NHS will be crucial to ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharmaceuticals' shares dropped due to poor first-quarter results. Vertex's business and prospects remain attractive. Vertex Pharmaceuticals (NASDAQ: VRTX), a leading drugmaker, is ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...